BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montenegro MF, González-Guerrero R, Sánchez-Del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN. PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation. Sci Rep 2020;10:13275. [PMID: 32764667 DOI: 10.1038/s41598-020-70289-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Wang D, Chen X, Wang W, Wang P, Hou P, Li M, Chu S, Qiao S, Zheng J, Bai J. PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death Dis 2021;12:1080. [PMID: 34775498 DOI: 10.1038/s41419-021-04381-5] [Reference Citation Analysis]
2 Carlos-Reyes A, Muñiz-Lino MA, Romero-Garcia S, López-Camarillo C, Hernández-de la Cruz ON. Biological Adaptations of Tumor Cells to Radiation Therapy. Front Oncol 2021;11:718636. [PMID: 34900673 DOI: 10.3389/fonc.2021.718636] [Reference Citation Analysis]
3 Wu Y, Liu H, Gong Y, Zhang B, Chen W. ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression. Bosn J Basic Med Sci 2021;21:294-304. [PMID: 32651974 DOI: 10.17305/bjbms.2020.4701] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW. PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer. J Pers Med 2021;11:1009. [PMID: 34683150 DOI: 10.3390/jpm11101009] [Reference Citation Analysis]
5 Cheng C, Pei X, Li SW, Yang J, Li C, Tang J, Hu K, Huang G, Min WP, Sang Y. CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing β-catenin. Oncogene 2021;40:2842-57. [PMID: 33742119 DOI: 10.1038/s41388-021-01692-x] [Reference Citation Analysis]
6 Repenning A, Happel D, Bouchard C, Meixner M, Verel-Yilmaz Y, Raifer H, Holembowski L, Krause E, Kremmer E, Feederle R, Keber CU, Lohoff M, Slater EP, Bartsch DK, Bauer UM. PRMT1 promotes the tumor suppressor function of p14ARF and is indicative for pancreatic cancer prognosis. EMBO J 2021;40:e106777. [PMID: 33999432 DOI: 10.15252/embj.2020106777] [Cited by in F6Publishing: 1] [Reference Citation Analysis]